Thierry Frebourg

Early onset hereditary hemochromatosis resulting from a novel TFR2 gene nonsense mutation (R105X) in two siblings of north French descent

T. Frebourg, C. Férec, G. Le Gac, 2004, British journal of haematology.

Selective detection of inactivating mutations of the tumor suppressor gene p53 in bladder tumors.

Cosette Martin, C. Martin, P. Grise, 1999, The Journal of urology.

TP53 mutations predict disease control in metastatic colorectal cancer treated with cetuximab-based chemotherapy

M. Ychou, T. Frebourg, F. Blanchard, 2009, British Journal of Cancer.

Clinical interest of KRAS mutation detection in blood for anti-EGFR therapies in metastatic colorectal cancer

T. Frebourg, F. Pessot, P. Michel, 2008, British Journal of Cancer.

Molecular profiling of bladder tumors based on the detection of FGFR3 and TP53 mutations.

T. Frebourg, F. Blanchard, C. Pfister, 2006, The Journal of urology.

Clinical relevance of KRAS mutation detection in metastatic colorectal cancer treated by Cetuximab plus chemotherapy

F. Blanchard, F. Pessot, F. Charbonnier, 2007, British Journal of Cancer.

Alternative splicing of MLH1 messenger RNA in human normal cells.

T. Frebourg, M. Scotté, Cosette Martin, 1995, Cancer research.